Target Australia chief resigns amid probe into rebate scheme
[SYDNEY] The managing director of Wesfarmers's Target department stores, Stuart Machin, resigned on Friday amid an investigation into whether the retailer inflated earnings by bringing forward supplier rebates.
Mr Machin denied involvement in the scheme to boost Target's first-half profit by seeking extra rebates from some 30 suppliers in return for promises of price rises in the second half. However, he said it was time to go. "Latterly, I have been dismayed to learn of the accounting issues at the half year," Mr Machin said in a statement released by Wesfarmers. "I was not aware of these, but they happened on my watch and as managing director I accept my share of the responsibility," he said. "The right thing is now for me to move on".
In December, Wesfarmers announced Mr Machin was shifting from his position as Target's managing director to a yet-to-be-identified senior executive role in July.
A Wesfarmers spokeswoman would not comment on earlier press reports that the rebates helped boost Target's first-half earnings by around 25 per cent.
The retailer's fiscal 2016 first-half earnings before interest and tax rose 5.7 per cent to A$74 million (S$75.4 million).
Wesfarmers has accepted Mr Machin's resignation which comes as an internal investigation into the rebates nears completion, according to the spokeswoman.
The Australian Target chain is not affiliated with the US group of stores of the same name.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Jim Beam owner bets on canned vodka cocktails to double revenue
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Cordlife served letter of demand, notice of claim from customers
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs